Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2855 Gazelle Court CARLSBAD CA 92010 |
Tel: | N/A |
Website: | https://www.ionispharma.com |
IR: | See website |
Key People | ||
Brett P. Monia Chief Executive Officer, Director | Elizabeth L. Hougen Chief Financial Officer, Executive Vice President - Finance | C. Frank Bennett Executive Vice President, Chief Scientific Officer |
Joseph T. Baroldi Executive Vice President, Chief Business Officer | Richard S. Geary Executive Vice President, Chief Development Officer | Kyle Jenne Executive Vice President - commercial |
Eugene Schneider Executive Vice President, Chief Clinical Development Officer | Eric E. Swayze Executive Vice President - Research | Patrick R. O'Neil Chief Legal Officer, General Counsel and Corporate Secretary |
Business Overview |
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company's products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN). |
Financial Overview |
For the three months ended 31 March 2024, Ionis Pharmaceuticals Inc revenues decreased 8% to $119.5M. Net loss increased 15% to $142.8M. Revenues reflect SPINRAZA royalties decrease of 23% to $38.5M. Higher net loss reflects Research and Development in COR/COGS increase of 8% to $192M (expense), Selling/General/Admin. Expense increase of 14% to $43.7M (expense), Interest expense - Balancing value increase from $8K to $4.1M (expense). |